Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 16/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17882067 | 0.94 | ELANE (0.66) | ELANELMNAALDH1A1ATML3MBTL1 | |
| SCHEMBL22369614 | 0.91 | ELANE (0.86) | ELANEPRTN3 | |
| SCHEMBL18882775 | 0.91 | ELANE (0.86) | ELANELMNAALDH1A1 | |
| SCHEMBL18882774 | 0.85 | ELANE (0.60) | ELANELMNAPRTN3 | |
| SCHEMBL10483745 | 0.84 | ELANE (1.00) | ELANEPRTN3 | |
| SCHEMBL13998362 | 0.84 | ELANE (0.76) | ELANEPRTN3 | |
| SCHEMBL8403640 | 0.84 | ELANE (0.81) | ELANEALDH1A1PRTN3 | |
| SCHEMBL12727385 | 0.83 | LMNA (0.55) | ELANELMNAALDH1A1ATML3MBTL1 | |
| SCHEMBL10457691 | 0.83 | ELANE (0.56) | ELANE | |
| SCHEMBL11596680 | 0.83 | ELANE (0.73) | ELANELMNAPRTN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102408285-B | Method for directly aminating benzyl hydrocarbon of methylbenzene derivative | UNIV NORTHEAST NORMAL | 2013-11-20 | — | — | CN | claimed |
| CN-119101089-A | Oligonucleotide synthesis process of chimeric PMO structure | 苏州盛诺维生物科技有限公司 | 2024-12-10 | — | — | CN | disclosed |
| CN-118993825-A | Method for preparing aromatic thioether derivative by promoting copper-mediated aryl C-H bond vulcanization by organic acid | 安徽工业大学 | 2024-11-22 | — | — | CN | disclosed |
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | FIREFLY BIO, INC. | 2024-07-04 | — | — | US | disclosed |
| US-11857635-B2 | Linker compound, polyethylene glycol-linker conjugate and derivative thereof and polyethylene glycol-linker-drug conjugate | JENKEM TECHNOLOGY CO., LTD. (TIANJIN) (CN) | 2024-01-02 | — | — | US | disclosed |
| US-20230364277-A1 | E-SELECTIN TARGETING AGENTS | GLYCOMIMETICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230265197-A1 | MONOCLONAL ANTIBODIES AGAINST HER2 EPITOPE AND METHODS OF USE THEREOF | MERSANA THERAPEUTICS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-11680074-B2 | Compounds, functionalised dioxaborolane or dioxaborinane derivatives, method for preparing same and uses thereof | ECOLE SUPERIEURE DE PHYSIQUE ET DE CHIMIE INDUSTRIELLES DE LA VILLE DE PARIS (FR) | 2023-06-20 | — | — | US | disclosed |
| US-11680074-B2 | Compounds, functionalised dioxaborolane or dioxaborinane derivatives, method for preparing same and uses thereof | ECOLE SUPERIEURE DE PHYSIQUE ET DE CHIMIE INDUSTRIELLES DE LA VILLE DE PARIS (FR) | 2023-06-20 | — | — | US | disclosed |
| US-20230167149-A1 | CD33 LIGANDS SUITABLE FOR INCORPORATION INTO CARRIERS | GLYCOMIMETICS, INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20120122679-A1 | MESOIONIC PESTICIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-05-17 | — | — | US | disclosed |
| CN-102408285-A | Method for directly aminating benzyl hydrocarbon of methylbenzene derivative | UNIV NORTHEAST NORMAL | 2012-04-11 | — | — | CN | disclosed |
| US-7342016-B2 | Farnesyl protein transferase inhibitors as antitumor agents | SCHERING CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
| US-7244847-B2 | Benzimidazole compounds | ISIS PHARMACEUTICALS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-6881522-B2 | Nonaqueous electrolytic solution and lithium secondary battery | UBE INDUSTRIES, LTD. (JP) | 2005-04-19 | — | — | US | disclosed |
| US-20040058251-A1 | Nonaqueous electrolytic solution and lithium secondary battery | HAMAMOTO TOSHIKAZU (JP) | 2004-03-25 | — | — | US | disclosed |
| EP-1311018-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND LITHIUM SECONDARY BATTERY | Ube Industries, Ltd. (JP) | 2003-05-14 | — | — | EP | disclosed |
| EP-0509769-B1 | Heterocyclic amides having HLE inhibiting activity | ZENECA LTD (GB) | 1996-09-11 | — | — | EP | disclosed |
| US-5521179-A | Heterocyclic amides | ZENECA LIMITED (GB) | 1996-05-28 | — | — | US | disclosed |
| EP-0509769-A2 | Heterocyclic amides having HLE inhibiting activity | ZENECA LIMITED (GB) | 1992-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11680074-B2 | Compounds, functionalised dioxaborolane or dioxaborinane derivatives, method for preparing same and uses thereof | RDX, XDH, NOX4 | ELANE 2138/4885LMNA 1743/4885ALDH1A1 944/4885 |
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | NR3C1, NR3C2, MC2R | ELANE 596/4885LMNA 4639/4885ALDH1A1 3778/4885 |
| US-20230167149-A1 | CD33 LIGANDS SUITABLE FOR INCORPORATION INTO CARRIERS | SIGLEC7, SIGLEC9, ASGR1 | ELANE 812/4885LMNA 2576/4885ALDH1A1 522/4885 |
| US-20230364277-A1 | E-SELECTIN TARGETING AGENTS | SELE, SELPLG, SELP | ELANE 13/4885LMNA 2712/4885ALDH1A1 940/4885 |
| US-20120122679-A1 | MESOIONIC PESTICIDES | CHRM2, CHRM5, CHRM1 | ELANE 2461/4885LMNA 3906/4885ALDH1A1 2621/4885 |
| US-20230265197-A1 | MONOCLONAL ANTIBODIES AGAINST HER2 EPITOPE AND METHODS OF USE THEREOF | ERBB2, EGFR, ERBB3 | ELANE 2144/4885LMNA 3887/4885ALDH1A1 4607/4885 |
| US-11857635-B2 | Linker compound, polyethylene glycol-linker conjugate and derivative thereof and polyethylene glycol-linker-drug conjugate | DCLRE1A, LANCL2, SI | ELANE 4482/4885LMNA 1871/4885ALDH1A1 1764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.